Fax: (713): 792-2031
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
Version of Record online: 31 JAN 2012
Copyright © 2012 American Cancer Society
Volume 118, Issue 12, pages 3123–3127, 15 June 2012
How to Cite
Huang, X., Cortes, J. and Kantarjian, H. (2012), Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer, 118: 3123–3127. doi: 10.1002/cncr.26679
- Issue online: 4 JUN 2012
- Version of Record online: 31 JAN 2012
- Manuscript Accepted: 5 OCT 2011
- Manuscript Revised: 23 SEP 2011
- Manuscript Received: 18 JUL 2011
- chronic myeloid leukemia;
- tyrosine kinase inhibitors;
- plateau prevalence;
The annual incidence of chronic myeloid leukemia (CML) in the United States is approximately 4800 cases. With the success of tyrosine kinase inhibitor (TKI) therapy, the all-cause annual mortality rate was reduced to 2%. Therefore, the prevalence of CML is increasing over time. Estimating the CML prevalence and plateau prevalence is important in the implementation of health care strategies and future therapeutic trials. The objective of this report was to estimate the increasing prevalence and plateau prevalence of CML in future years.
The prevalence of CML was estimated based on several parameters: the annual mortality rate on TKI therapy compared with a age-matched, normal population; the incidence of CML; the anticipated population growth in the United States; and aging of the population.
On the basis of these calculations, the mortality ratio of patients with CML compared with an age-matched normal population was approximately 1.53. The estimated prevalence of CML is approximately 70,000 in 2010, 112,000 in 2020, 144,000 in 2030, 167,000 in 2040, and 181,000 in 2050, when it will reach a near plateau prevalence.
The current results indicated that the prevalence of CML will continue to increase to reach a near plateau prevalence 35 times the annual incidence. These estimates should be considered in health care policies and in the design of future studies in CML. Cancer 2012;118: 3123–27. © 2012 American Cancer Society.